Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
34.7M
-
Number of holders
-
71
-
Total 13F shares, excl. options
-
17.7M
-
Shares change
-
-171K
-
Total reported value, excl. options
-
$244M
-
Value change
-
-$3.03M
-
Put/Call ratio
-
0.09
-
Number of buys
-
34
-
Number of sells
-
-39
-
Price
-
$13.74
Significant Holders of IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) as of Q1 2023
90 filings reported holding IGMS - IGM Biosciences, Inc. - Common Stock, par value $0.01 per share as of Q1 2023.
IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) has 71 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.7M shares
of 34.7M outstanding shares and own 51.11% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (3.33M shares), BAKER BROS. ADVISORS LP (3.16M shares), Artal Group S.A. (2.51M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.12M shares), FMR LLC (846K shares), BlackRock Inc. (771K shares), ALKEON CAPITAL MANAGEMENT LLC (712K shares), VANGUARD GROUP INC (580K shares), UBS ASSET MANAGEMENT AMERICAS INC (485K shares), and GOLDMAN SACHS GROUP INC (394K shares).
This table shows the top 71 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.